Nurtec ODT (rimegepant)

Nurtec ODT is called Vydura ODT internationally.

Information about Nurtec ODT (rimegepant)

Nurtec ODT (brand name for rimegepant) is an oral medication primarily used to treat and prevent migraines. It is part of a class of medications called CGRP (calcitonin gene-related peptide) receptor antagonists. Rimegepant works by blocking the CGRP receptors, which are involved in the dilation of blood vessels in the brain that contribute to migraine attacks. By inhibiting CGRP, Nurtec helps alleviate migraine symptoms and reduce the frequency of attacks.

Nurtec ODT is a fast-dissolving, orally disintegrating tablet (ODT), which allows for convenient administration without the need for water.

Product Highlights

• Nurtec ODT is used to treat acute migraine attacks with or without aura in adults. It is not meant for the treatment of tension headaches or other types of headaches.
• Rimegepant is also indicated for the preventive treatment of episodic migraines (fewer than 15 headache days per month) in adults. This provides a dual benefit of reducing the frequency of migraines and alleviating acute symptoms.

Key Ingredient

• Rimegepant

Key Benefits

• Patients often experience relief from migraine pain within 1-2 hours of taking Nurtec ODT.
• As an orally disintegrating tablet, Nurtec ODT dissolves quickly on the tongue, which is especially beneficial for patients who may have difficulty swallowing pills or need a treatment they can take without water.
• It treats acute migraine attacks and can also be used for long-term migraine prevention, offering flexible treatment options.
• Unlike some other migraine medications, rimegepant does not cause drowsiness, so it allows patients to maintain their normal daily activities.
• Since Nurtec ODT is not a triptan and is not habit-forming, it is associated with a lower risk of medication overuse headaches compared to some other migraine treatments.

Direction of Use

• The recommended dose of Nurtec ODT for acute treatment of migraine is 75 mg (one tablet) taken at the onset of a migraine attack. If the migraine persists, a second dose can be taken after at least 24 hours, but not more than one dose should be taken within a 24-hour period.
• For the prevention of episodic migraines, Nurtec ODT is typically taken as 75 mg once a day. Your healthcare provider will adjust the dosing schedule based on individual needs and response.
• The tablet should be placed on the tongue where it will dissolve rapidly. There is no need for water, making it a convenient option for on-the-go use.

Safety Concerns

• Some people may experience allergic reactions to rimegepant, including rash, itching, or swelling. Seek medical attention if any signs of a serious allergic reaction occur.
• Rimegepant is metabolized by the liver, so individuals with liver problems should be cautious. Regular liver function tests may be needed.
• Although no dose adjustment is typically required for patients with mild or moderate renal impairment, patients with severe renal impairment should avoid using Nurtec ODT.
• Rimegepant may interact with other medications, particularly those that affect liver enzymes. Patients should notify their healthcare provider about all medications they are taking, including prescription drugs, over-the-counter medications, and supplements.
• The safety of Nurtec ODT during pregnancy and breastfeeding has not been established. It should be used during pregnancy only if the potential benefits outweigh the potential risks to the fetus. It is unknown whether rimegepant passes into breast milk, so caution is advised for breastfeeding women.

Avoid Nurtec ODT (rimegepant) If:

• Individuals with a known allergy to rimegepant or any of the ingredients in Nurtec ODT should avoid using this medication.
• Patients with severe hepatic impairment should not use Nurtec ODT because the drug is metabolized by the liver and may cause adverse effects.
• Those with severe renal impairment (e.g., creatinine clearance < 30 mL/min) should avoid using Nurtec ODT as the drug has not been well studied in these populations.
• Drugs that strongly inhibit CYP3A4 may increase the concentration of rimegepant, and concurrent use should be avoided.